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INTRODUCTION
Promyelocytic leukemia protein (PML) was first identi-
fied as the product of the promyelocytic leukemia gene
(PML) that fuses with the retinoic acid receptor  (RAR )
gene in the t (15;17) translocation of acute promyelocytic
leukemia (APL) (1). PML-RAR is known to be a domi-
nant negative oncoprotein that exerts its putative leuke-
mogenic effect by inhibiting assembly of the distinctive
nuclear structure, PML nuclear body (NB) (2). Meanwhile,
immunolocalization studies using sera from patients with
autoimmune diseases showed that the PML was diffusely
present within the nucleus and/or localized to distinctive
“multiple nuclear dots” , which were originally described as
an autoantigenic target in a patient with primary biliary
cirrhosis (3). PML NBs vary in number between 10 and 30
per nucleus, and typically have a diameter of between 0.2
and 1 m. The number, size, and morphology of PML NBs
alter throughout the cell cycle (4, 5) and are also dynamical-
ly changed by diverse extracellular environment including
DNA and RNA viral infection (6-8).
Although it is well documented the proper organization
of PML NBs is essential for normal cell proliferation and
hematopoietic differentiation (9), the functions of PML or
PML NBs still remain elusive in the pathogenesis of inflam-
matory and neoplastic diseases except APL. The PML expre-
ssion was considerably upregulated in inflammatory tissues
such as hepatitis as well as during either normal or patho-
logical proliferative states including benign or malignant
tumors (4, 10-13). In most of malignant solid tumors
examined, the PML was markedly overexpressed and orga-
nization of PML NBs was not disturbed, unlike in cases of
APL (13-15). Variable PML expression in human solid tumors
suggests that the PML may play another role in addition to
as a tumor suppressor, inducer of apoptosis and a depot of
viral proteins (16, 17), and the mechanism of PML expres-
sion can be different from that of leukemogenesis.
Among solid neoplasms in which the PML is overex-
pressed, we selected hepatocellular carcinomas (HCCs) by
the following indications: first, the expression of PML is
quite different between non-neoplastic hepatocytes and
HCC cells (13, 14); secondly, most of hepatocytes are in G0
phase of cell cycle, while a significant fraction of HCC cells
are in actively proliferative stage; thirdly, hepatocellular car-
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Overexpression of Promyelocytic Leukemia Protein and Alteration of
PML Nuclear Bodies in Early Stage of Hepatocarcinogenesis
Promyelocytic leukemia protein (PML) is a major component of PML nuclear
bodies (PML NBs). Fusion of promyelocytic leukemia gene (PML) with retinoic
acid receptor gene with the t (15;17) translocation causes disassembly of PML
NBs, leading to development of acute promyelocytic leukemia. In contrast, PML
overexpression as well as different morphological changes of PML NBs were
described in a few solid tumors. In this study, the expression of PML through the
multistep hepatocarcinogenesis was analyzed in 95 cases of human hepatocel-
lular carcinomas (HCCs) for comparison along with dysplastic nodules (DNs)
and background liver cirrhosis (LC) or chronic hepatitis by immunohistochem-
istry and immunoblot. In addition, cases of HCCs were further evaluated accord-
ing to their histologic grade and etiology. The amount of PML as well as the num-
ber and size of PML NBs increased gradually through the progression from LC,
DNs to HCCs. The overexpression of PML in HCCs was much more closely
associated with HBV infection than HCV infection or alcoholic liver disease. The
PML expression, however, was not correlated with histologic grade of HCCs.
These results suggest that PML is involved in the early stage of multistep hepa-
tocarcinogenesis, and HBV infection may be associated with the overexpression
of PML and the morphological alteration of PML NBs.
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cinogenesis is typical of a multistage process from chronic
liver disease including liver cirrhosis (LC) through dysplas-
tic nodule (DN) to HCCs (18), thus the PML expression
can be properly correlated with the corresponding patho-
logic conditions.
MATERIALS AND METHODS
Tissue samples
Ninety-five cases of surgically resected HCCs were select-
ed from the surgical pathology files of the Department of
Pathology, Asan Medical Center, Seoul, Korea or Depart-
ment of Pathology, Mt. Sinai Hospital, New York Universi-
ty, NY, U.S.A. Seventy-five cases were positive for HBV
DNA or HBs antigen. Ten cases of HCCs were positive for
HCV RNA and had no evidence of HBV infection and
another 10 cases had past medical history of chronic alco-
holism and were negative for HCV RNA, HBs or HBc
antigens. Six cases of HCCs developed within a DN and
three cases had a separate DN each. Serial sections of forma-
lin-fixed and paraffin-embedded tissues from HCCs and
non-neoplastic livers were cut for hematoxylin and eosin
stain and immunohistochemistry.
Histologic features of HCCs were classified according to
the grading system of Edmondson and Steiner (19) and
those of non-neoplastic livers were reviewed.
Among 75 cases, fresh frozen tissues from HCCs and cor-
responding nontumor livers were available in 9 cases, one of
which had both DN and HCC.
Cell culture
HepG2, HepG2.2.15 (20) and Hep3B cells were main-
tained in DMEM (Gibco, Gaithersburg, MD), supplement-
ed with 10% fetal calf serum at 37℃ in a humidified
atmosphere containing 5% CO2. 
Immunohistochemical and immunofluorescent staining
Immunohistochemistry was done following streptavidin
biotin complex method after antigen retrieval by boiling
twice in citrate buffer (pH 6.0) for 5 min as previously
described (21). The primary antibody for PML used in this
study was PG-M3 (Santa Cruz, California, U.S.A., 1:100
dilution). For immunofluorescent staining, cultured cells on
coverslips were fixed in cold methanol for 10 min. Fluores-
cein-conjugated anti-mouse immunoglobulin was com-
plexed with the primary antibodies for 1 hr. The tissue sec-
tions or cells were mounted with Fluoromount G (Fischer
Scientific Co., Pittsburgh, PA) and examined by using
Olympus light microscope, Olympus Venox fluorescent
microscope or Zeiss confocal laser scanning microscope.
Expression of the PML was described as follows: 1) aver-
age number of PML NB-positive cells per 1,000 hepato-
cytes or HCC cells: 2) average number of PML NBs in one
nucleus of hepatocytes or HCC cells: 3) shape of PML NBs
as fine dots, large dots greater than 1.0  m in diameter, or
ball-shaped NBs.
Immunoprecipitation and immunoblotting
Preparation of nuclear proteins was done as previously
described (21). Protein amount was calibrated by using
BCA protein assay. Twenty  g from the supernatant of each
sample was incubated with the anti-PML antibody, PG-M3
at 1:200 dilution coupled to protein A-sepharose for 1 hr at
4℃. After extensive washing with the buffer, bound pro-
teins were separated by SDS-PAGE and transferred to nitro-
cellulose papers which were allowed to react with the anti-
PML antibodies for 1 hr. Immune complexes were detected
by the chemiluminescence detection system (Amersham
Pharmacia Biotech LtD, UK).
Statistical analysis
The significance of differences in the expression of PML
of HCCs, DNs, LC and chronic hepatitis (CH) was estimat-
ed by paired t-test, Two-sample test, one way analysis of
variance (ANOVA) procedure. The level of statistical signif-
icance was set at 95% for all evaluations.
RESULTS
PML expression in non-neoplastic liver
Seventy-one cases of HCCs were associated with LC and
24 cases occurred in the background of chronic hepatitis
(CH). In non-neoplastic liver, rare hepatocytes showed one or
two PML NBs that were slightly variable in size and shape
(Fig. 1A). The difference of average number of PML NB-
positive hepatocytes between CH and LC was not statistical-
ly significant (Table 1). Most of the reactive hepatocytes in
CH and regenerating hepatocytes in LC that revealed PML
NBs were unevenly distributed and closely associated with
portal inflammatory cells. Average number of PML NBs in
one hepatocyte nucleus was also higher in LC than that in
CH, which was not statistically significant (Table 1).
PML expression in dysplastic nodules
Nine cases of DN were associated with HCCs in the back-
ground of LC. Average number of PML NB-positive hepa-
tocytes was significantly increased in DNs compared with
that in adjacent LC or CH (p<0.05) (Table 1). Six of nine
cases of DN were classified low grade and three were highPromyelocytic Leukemia Protein in Hepatocellular Carcinoma 435
grade. There was also a difference in number of PML NB-
positive hepatocytes between low (31.27±43.26/1,000
cells) and high grade DNs (72.72±29.69/1,000 cells)
(p<0.05 by paired t-test). The number of PML NBs in one
hepatocyte nucleus was higher in DN than in LC, which
was not statistically significant. Most of PML NBs were
enlarged and some of them were ball-shaped with an empty
center (Fig. 1B).
PML expression in hepatocellular carcinomas
The average number of PML NB-positive HCC cells per
1,000 HCC cells was markedly increased. The differences in
average number of PML NB-positive cells between HCC,
DN and LC were statistically significant (Table 1). The
number of PML NBs per nucleus was also higher in HCC
than in DN, LC and CH, which was not statistically signifi-
cant (Table 1). Shape of PML NBs was quite different as
well: greater than 50% of PML NBs in HCCs were large
solid dots or ball-shaped with an empty core (Fig. 1C).
The average number of PML NB-positive HCC cells was
greater in HCCs associated with HBV than in HCCs associ-
ated with HCV or alcohol (Table 2). The number of PML
NBs per one tumor cell nucleus was also higher in HBV-
associated HCCs than in HCV-associated HCCs or alcohol-
associated HCCs (Table 2). The shape of PML NBs, howev-
*HCC, hepatocellular carcinoma; DN, dysplastic nodule; LC, liver cirrho-
sis; CH, chronic hepatitis; PML, promyelocytic leukemia protein; PML
NB, PML nuclear body; 
� HBV vs HCV and HBV vs alcoholic, p<0.05
according to one way Analysis of Variance (ANOVA) procedure
Etiology 
(No.of cases)
PML expression 
No. of
PML NB/nucleus
No. of
PML NB + cells/1,000 cells
HBV (75) 100.31±83.71
� 4.2±1.84
HCV (10) 80.62±39.43 2.4±0.56
Alcohol (10) 48.43±45.28 2.7±1.79
Table 2. Expression of PML in 95 cases of hepatocellular carci-
noma according to etiologies
*HCC, hepatocellular carcinoma; DN, dysplastic nodule; LC, liver cir-
rhosis; CH, chronic hepatitis; PML, promyelocytic leukemia protein;
PML NB, PML nuclear body; 
� HCC vs DN, HCC vs LC and HCC vs CH,
p< 0.05 according to paired T-test; 
� DN vs LC and DN vs CH, p<0.05
according to Analysis of Variance(ANOVA) procedure: Duncan's multi-
ple range test
Diagnosis
(No.of cases)
PML expression 
No. of
PML NB/nucleus
No. of
PML NB + cells/1,000 cells
HCC (95) 92.81±78.31
� 3.8±1.86
DN (9) 45.09±46.43
� 2.8±1.26
LC (71) 8.95±7.66 1.8±1.54
CH (24) 4.70±6.15 0.5±0.50
Table 1. Expression of the PML in hepatocellular carcinomas,
dysplastic nodules, liver cirrhosis and chronic hepatitis
*HCC, hepatocellular carcinoma; DN, dysplastic nodule; LC, liver cir-
rhosis; CH, chronic hepatitis; PML, promyelocytic leukemia protein;
PML NB, PML nuclear body
Histologic grade
(No.of cases)
PML expression 
No. of
PML NB/nucleus
No. of
PML NB + cells/1,000 cells
1 (12) 93.75±106.5 4.5±2.40
2 (40) 99.37±80.93 3.5±1.72
3 (33) 88.43±68.25 3.8±1.80
4 (10) 80.62±65.31 4.6±1.64
Total cases (95) 92.81±78.31 3.8±1.86
Table 3. Expression of the PML in 95 cases of hepatocellular
carcinomas according to histologic grade 
A B C
Fig. 1. PML expression in liver cirrhosis (A), dysplastic nodule (B), and hepatocellular carcinoma (C): A, Only one or two dots of PML
NBs (arrows) are noted in regenerating hepatocytes. B, PML NBs are enlarged and some of them are ball-shaped (arrow). C, Most
of PML NBs in HCC cells are markedly enlarged with empty cores (original magnification, ×1,000).436 G.-S. Yoon, E.S. Yu
er, was similar in all HCCs. There was no significant corre-
lation between the PML expression and histologic grade
(Table 3). Pleomorphic nucleus in high grade HCCs, how-
ever, had greater number of much larger or ball-shaped
PML NBs than in lower grade HCCs.
Differential overexpression of the PML in HCC compared
with those in LC and DN was confirmed by immunoblot-
ting in a case that had both DN and HCC in the back-
ground of LC (Fig. 2).
PML expression in hepatocellular carinoma cell lines
To examine the effect of HBV infection, we compared the
expressions of PML in HepG2, HepG2.2.15, and Hep3B
cells. HepG2.2.15 is a stable cell line that has been trans-
fected by whole HBV genome in HepG2 cells and produce
HBV DNA (20). HepG2 was established from a human
hepatoblastoma and is not associated with HBV infection.
Hep3B is a human hepatocellular carcinoma cell line pro-
ducing HBV DNA and antigens. Five to ten PML NBs
were detected in all HepG2 cells in interphase. Their shape
was monotonous and about 0.5  m in size (Fig. 3A). In
HepG2.2.15 and Hep3B cells, the number of PML NBs
was similar, but more than 50% of PML NBs were enlarged
up to 1-2  m with an empty core (Fig. 3B).
DISCUSSION
The development and progression of HCC is typical of a
multistep process from chronic liver disease caused by viral
infection or toxic substance through DN to early or advan-
ced HCC with genetic and/or epigenetic alterations. Thus,
we analyzed the PML expression in HCCs as well as DNs
and adjacent non-neoplastic liver tissues in the present
study. Although the PML is known to be present diffusely
in the nucleoplasm or in PML NBs, the PML was localized
mainly to PML NBs as revealed by immunohistochemical
staining with the monoclonal antibody, PG-M3. Thus, we
described the PML expression according to the number of
PML NB-positive hepatocytes or HCC cells per 1,000 hep-
atocytes or HCC cells and the number of PML NBs in one
nucleus of hepatocyte or HCC cell.
The differential overexpression of the PML in DN and
HCC in this study indicates that the PML expression is dif-
ferentially regulated during the multistep hepatocarcino-
genesis, and the alteration of the PML expression may occur
first in the early stage of hepatocarcinogenesis, from LC to
DN formation. In contrast to our results, Chan et al. (15)
described overexpression of the PML in the PML NBs in
50% of human HCCs and most of non-tumorous cirrhotic
liver, thus indicated that the PML overexpression was asso-
ciated with both LC and HCC formation. Gambacorta et al.
(13) reported the PML expression in 10/10 liver tumors,
but neither histologic grading of the HCCs nor compara-
tive analysis between preneoplastic lesions and HCCs has
been made. The immunoprecipitation with immunoblot
analysis in a few representative cases of HCCs supported
also a distinct overexpression of the PML in DN and HCC
compared with non-neoplastic liver. To clarify a possibility
of transcriptional upregulation, northern blot analysis using
RT-PCR products of the PML in LC, DN and HCC has
been undergoing. At this moment, however, it can not be
determined whether the overexpression of the PML in DNs
250
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Fig. 2. Immunoprecipitation and immunoblot analysis for the
PML in a case of hepatocellular carcinoma (HCC) with dysplas-
tic nodule (DN) in a background of liver cirrhosis (LC). Note dif-
ferential overexpression of the PML (arrow) in LC, DN and HCC.
*, immunoglobulin heavy chain. 
Fig. 3. PML NBs in HepG2 (A) and HepG2.2.15 cells (B) by
confocal scanning microscope. Note enlarged ball-shaped
PML NBs in HepG2.2.15 compared with a few fine dots in
HepG2 cells (original magnification, ×1,000). 
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and HCCs is a cause for hepatocellular carcinogenesis or an
epiphenomenon during hepatocarcinogensis.
Statistically significant difference of the PML expression
between HBV-associated HCCs and HCV- or alcohol-associ-
ated HCCs and morphological characteristics of PML NBs in
HepG2.2.15, a stably transfected cell line by HBV genome,
suggest a strong relationship between HBV infection and
PML NBs. PML NBs are known to be the site of DNA virus
transcription and replication (8), thus HBV infection may
affect the size or shape of PML NBs. Aoki et al. (22) reported
that a subgenomic HBV DNA sequence (15 AB) is a hot spot
for genomic recombination and a portion of 15AB-like
sequence is homologous to break-point clusters of the human
PML gene. Considering a close relationship between HBV
infection and HCCs, it may be suggested that the PML might
be a recombinogenic candidate triggering genomic instability
in HBV-associated hepatocarcinogenesis. The structure of ball-
shaped PML NBs is known to be associated with a recruit-
ment of other PML NB-associated proteins such as SUMO-1
(23, 24) and TRF1 or TRF2 (25), and assembly with PML
within PML NBs. Thus a further analysis of coimmunopre-
cipitates with PML and PML isoforms in LC, DN and HCC
using two-dimensional gel electrophoresis may elucidate an
alternative mechanism of the PML overexpression and the
morphological alteration of PML NBs.
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